Abstract | OBJECTIVE: METHOD: An open-label study of guanfacine was performed in 10 children with TS+ADHD, aged 8 to 16 years. The duration of follow-up was 4 to 20 weeks, and the majority of subjects were treated with 1.5 mg/day. Ratings of tic severity and ADHD symptoms were obtained using the Yale Global Tic Severity Scale (YGTSS), the Tic Symptom Self Report (TSSR), and the Conners Parent Rating Scale. In addition, blind Continuous Performance Tests (CPTs) were performed at baseline and at two follow-up intervals in eight subjects. RESULTS:
Guanfacine was associated with significant decreases in both commission errors (p < .02) and omission errors (p < .01) on the CPT. In addition, guanfacine caused a significant decrease in severity of motor (p < .02) and phonic (p < .02) tics as measured by the TSSR and the YGTSS, respectively. The most common side effects were transient sedation and headaches. CONCLUSION:
Guanfacine may provide a safe alternative therapy for children with ADHD in the presence of tics. Future double-blind, controlled trials should be undertaken.
|
Authors | P B Chappell, M A Riddle, L Scahill, K A Lynch, R Schultz, A Arnsten, J F Leckman, D J Cohen |
Journal | Journal of the American Academy of Child and Adolescent Psychiatry
(J Am Acad Child Adolesc Psychiatry)
Vol. 34
Issue 9
Pg. 1140-6
(Sep 1995)
ISSN: 0890-8567 [Print] United States |
PMID | 7559307
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Adrenergic Agonists
- Guanfacine
|
Topics |
- Adolescent
- Adrenergic Agonists
(adverse effects, therapeutic use)
- Attention Deficit Disorder with Hyperactivity
(diagnosis, drug therapy)
- Child
- Female
- Follow-Up Studies
- Guanfacine
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Psychological Tests
- Tourette Syndrome
(diagnosis, drug therapy)
- Treatment Outcome
|